Tumor treating fields (TTF or TTFields), are low intensity, electric fields alternating at an intermediate frequency that have been shown to disrupt cell division and interfere with organelle assembly during mitosis in solid tumor cancers. A novel treatment modality, TTF are continuously delivered by 4 transducer arrays consisting of 9 insulated electrodes each. These arrays are placed on the patient’s shaved scalp and connected to a portable device. Tumor treating fields has demonstrated promise in treating glioblastoma when administered together with temozolomide chemotherapy in newly diagnosed disease. The TTF protein is also known as the thyroid specific enhancer binding protein. It is useful as an important marker to determine the diagnosis of tumors.